Select Page ::

Grey's Anatomy, Thursday, February 16

Posted on February 15, 2012 by Danzig

Patrick Dempsey.

Reviewer rating:

Rating: 15 out of 5 stars

Reader rating:

Rating: 40 out of 5 stars (305 votes)

Channel Seven, 8.30pm

It's hard to decide what is the most annoying element of this inexplicably enduring hospital drama. The silliness and preening of the characters and their dial-up romantic traumas? The sanctimonious speeches delivered without a speck of irony by the po-faced Dr Meredith Grey (Ellen Pompeo)? The bland and mechanical treatment of the medical cases that are ferried into the emergency department (and who, in any case, are routinely shunted aside for the medicos' seemingly more pressing concerns)? The wall-to-wall soundtrack of saccharine songs that fills the gaps where the drama is meant to be? Tonight, Meredith, having already lost her job, goes AWOL and puts her's and Derek's custody of their adopted daughter at risk. Where is she and why? Who knows? Who cares?

See the original post here:
Grey's Anatomy, Thursday, February 16

Bone gives ‘some’ heart healing

Posted on February 15, 2012 by ev1

14 February 2012 Last updated at 19:10 ET By James Gallagher Health and science reporter, BBC News

Bone marrow stem cell therapy offers "moderate improvement" to heart attack patients, according to a large UK review of clinical trials.

The analysis by the Cochrane Collaboration looked at 33 trials involving more than 1,700 patients.

It said longer-term studies were needed to see if the experimental therapy affected life expectancy.

The review comes a day after doctors reported the first case of using heart cells to heal heart attack damage.

If a patient survives a heart attack, dead heart muscle is replaced with scar tissue - leaving the patient weaker and possibly on a lifetime of medicine.

Researchers are beginning to show that taking cells from a heart, growing millions of new heart cells in the laboratory and pumping those back into the heart may reduce scar tissue and lead to new heart muscle.

Continue reading the main story “Start Quote

Stem cell therapy may also reduce the number of patients who later die or suffer from heart failure, but currently there is a lack of statistically significant evidence based on the small number of patients treated so far”

End Quote Dr Enca Martin-Rendon Lead researcher

However, the trials are at a very early stage and in only a handful of patients. Using a similar technique with cells taken from the bone marrow, which is a prime source of stem cells, has a much longer pedigree.

The report by Cochrane pooled the data from all 33 bone marrow trials which had taken place up to 2011.

It concluded that bone marrow therapy "may lead to a moderate long-term improvement" in heart function which "might be clinically very important".

Longer life uncertain

It said there was still no evidence of "any significant effect on mortality" in comparison with standard treatment. However, this may be due to the size of the studies and that patients were followed for a short period of time.

Lead author Dr Enca Martin-Rendon, from NHS Blood and Transplant at the John Radcliffe Hospital in Oxford, said: "This new treatment may lead to moderate improvement in heart function over standard treatments.

"Stem cell therapy may also reduce the number of patients who later die or suffer from heart failure, but currently there is a lack of statistically significant evidence based on the small number of patients treated so far."

Prof Anthony Mathur, from Barts and the London School of Medicine and Dentistry, is leading the largest ever trial of stem cells in heart attack patients.

It starts this year, however, he told the BBC that the results could come quite quickly. Three thousand patients across Europe will take part. They will be injected with stem cells five days after a heart attack and then followed for two years to see if the therapy affects life expectancy.

Prof Peter Weissberg, medical director at the British Heart Foundation, said: "This review reflects the consensus of opinion about these trials - cell therapy has a modestly beneficial effect.

"Despite that, no-one knows why, or even if, cell therapies will translate into better survival or sustained improvement in damaged hearts. It's much too early to judge the likely long-term benefits."

Visit link:
Bone gives 'some' heart healing

DNA collection bill causes controversy

Posted on February 15, 2012 by ev1

TACOMA—

The fight over collecting DNA from anyone arrested for a serious crime is heating up in Olympia.

Opponents call it an invasion of privacy, but prosecutors say House Bill 2588 could be their best crime-fighting tool to keep repeat offenders off the street.

Pierce County Prosecutor Mark Lindquist cited a 2005 serial rape case as an example. Anthony Dias raped more than a dozen women, including two underage girls, before he was caught.

HB 2588 requires police to collect a DNA cheek swab from anyone arrested for a felony; DNA that would then be put into a national databank.

“Currently when someone is arrested, that person is searched, photographed and fingerprinted. A cheek swab is no more intrusive than a fingerprint or photograph,” Lindquist said.

Shankar Narayan, of the American Civil Liberties Union, testified against the bill, saying it's a violation of the Fourth Amendment's right against unreasonable search and seizure.

“We want to see the types of crimes prevented as well, but unfortunately this bill isn't the right way to do it,” Narayan said. “The intrusiveness of the search is a big concern for us, and a lot of innocent people are going to be swept up in this and have DNA taken through no fault of their own.”

If this law was in place in 2005, prosecutors say, Dias would have been stopped. That's because before he assaulted 19 victims in Pierce and King County, he was arrested for a felony hit-and-run and would have been subjected to a DNA swab at that time.

Under this bill, supporters argue, the DNA would not be put into the databank until a judge finds probable cause, and if the case is eventually dismissed, the DNA would be destroyed.

The measure would cost about $400,000 a year, funding that would come from traffic violations. The bill must move off the House floor Tuesday night to survive.

Read more from the original source:
DNA collection bill causes controversy

TRADE NEWS: Agilent Technologies Introduces First DNA Methylation Target-Enrichment System for Disease Research

Posted on February 15, 2012 by ev1

MARCO ISLAND, Fla.--(BUSINESS WIRE)--

(AGBT) – Agilent Technologies Inc. (NYSE:A) today expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites. It is the first comprehensive DNA methylation discovery system using target enrichment. Agilent will unveil the product at the Advances in Genome Biology and Technology meeting here tomorrow.

Agilent SureSelect XT Methyl-Seq is a unique in-solution tool for analyzing under- and over-methylated cytosine sites on the human genome. The assay combines SureSelect, the leading target-enrichment platform, with bisulfite sequencing, the gold standard for DNA methylation research and the first comprehensive discovery system. This enables unprecedented sequence coverage of only the most relevant regions for epigenetic studies, including those associated with a wide range of disorders such as cancer, imprinting disorders, behavioral and mental disorders, and many others.

“DNA methylation is a key epigenetic feature,” said John Stamatoyannopoulos, director of the Northwest Reference Epigenome Mapping Center at the University of Washington. “The availability of a cost-effective platform that intelligently targets millions of CpGs for bisulfite sequencing will greatly reduce the cost and expand the scope and utility of genome-scale DNA methylation analysis.”

“The kit covers all interesting methyl-cytosine sites for cancer research in the genome at an excellent effort-to-output ratio,” said Michal-Ruth Schweider, MD, Ph.D., Max Planck Institute for Molecular Genetics.

“We’re very pleased to offer this new tool to meet growing interest from the medical research community,” said Robert Schueren, Agilent vice president and general manager, Genomics. “Because abnormal methylation is reversible, this type of analysis holds great promise for the discovery of therapies.”

Agilent SureSelect XT Methyl-Seq allows researchers to analyze over 3.7 million individual CpG dinucleotide sequences for their methylation state. The system targets promoters, canonical CpG islands, and the more recently described “shores” and “shelves” found up to 4 kilobase pairs on either side of CpG islands. Studies have indicated that many methylation alterations are not in promoters or CpG islands, but most are within 2kb, the CpG island shore. The kit also targets known differentially methylated regions.

Agilent SureSelect XT Methyl-Seq delivers higher throughput and lower costs than whole genome bisulfite sequencing. It identifies regions that are not detected by restriction enzyme-based or immunoprecipitation-based methods. Because this product is a SureSelect XT offering, Agilent provides the complete workflow solution. This includes all reagents needed for library prep and target enrichment.

For more information, visit http://www.agilent.com/genomics/ngs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A - News) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company’s 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at http://www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at http://www.agilent.com/go/news.

View original post here:
TRADE NEWS: Agilent Technologies Introduces First DNA Methylation Target-Enrichment System for Disease Research

Grey's Anatomy with guns

Posted on February 15, 2012 by Danzig

JULE SCHERER

It's not easy to like Gail Peck, but actress Charlotte Sullivan who plays the young officer in Canadian cop show Rookie Blue says she doesn't mind.

Peck is one of five rookie police officers that the TV show - returning for a second season tonight on TV2 - follows as they take their first steps on the job.

"I don't play her for people to like her, she is really eccentric and quite cryptic and strange and I adore playing her," the 28-year old actress says.

"Its seems that she doesn't give a s**t what other people think about her but in actuality it is a little bit more complicated and she wants to be accepted into the pack, she just doesn't know how."

But Sullivan is quick to point out, that there are four other characters to like on the show: There's the lead character, Andy McNally (Missy Peregrym), the over eager Dov Epstein (Gregory Smith), the practical and responsible Traci Nash (Enuka Okuma) and Chris Diaz (Travis Milne) who tends to do everything by the book.

The one thing that sets Rookie Blue apart from other cop shows, she says, is that the protagonists are beginners.

"We're not seasoned, we don't know what we doing," Sullivan explains.

"In most cop shows it's all about people who are well trained and know what they're doing.

"Our show is the beginning of a cop career, the very first time they put on their walkie-talkie, the first time they put on their badge, the first time they put on their vest and even though they had an extensive amount of training, it's still the first day on the job and their nerves are so tightened.

"You're not watching a cop show where they're well established and they never screw up - that's a job of a rookie, you screw up and learn and you do it again."

When she was first offered the role, Sullivan doubted she could play a police officer.

"I thought I couldn't do that job because of my physicality, I think of myself as all noodle arms and not very coordinated and you associate cops with being incredibly athletic and I am terrible at sports.

"I think being a police officer would be one of the hardest job and I am so grateful that I only get to put the uniform on for a job and take it off at night and go home to my real life," she says.

Speaking of putting on the uniform, the petite blonde, who played Marilyn Monroe in last year's mini series The Kennedys, is glad to have talented costume designers in charge of her tailor-made the outfits."

"A lot of cops come up to us and say 'I love your uniform' because everybody gets the run-of-the-mill standard uniform in real-life and ours are kind of tweaked to flatter our figures."

Rookie Blue has often been dubbed Grey's Anatomy with guns, a comparison Sullivan relishes.

"It's the most flattering comparison because that show also writes women in a really intelligent fashion," she says.

"I think if you take the same premises, five rookie cops, or five new interns going to a hospital for the first time and are learning on the job it's the same sort of concept."

For the second season Sullivan is promising more drama between the characters.

"Gail, without asking, has moved herself into Chris and Dov's apartment

"She wants to mend Chris' wounds after he's been shot but he so healthy and so fine," she reveals.

And there's even more conflict on the cards, when Chris confesses his undying love for Gale.

"Just when you think their personal relationships are fine it turns a new corner in the next episode," she says.

-Rookie Blue, Tuesdays 9.30pm, TV2

See the original post:
Grey's Anatomy with guns

Freeze-dried heart valve scaffolds hold promise for heart valve replacement

Posted on February 15, 2012 by ev1

Public release date: 14-Feb-2012
[ | E-mail | Share ]

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY -- The biological scaffold that gives structure to a heart valve after its cellular material has been removed can be freeze-dried and stored for later use as a tissue-engineered replacement valve to treat a failing heart, as described in an article in Tissue Engineering, Part C: Methods, a peer-reviewed journal from Mary Ann Liebert, Inc. (http://www.liebertpub.com). The article is available free online at http://www.liebertpub.com/ten

Shangping Wang and colleagues from Leibniz University, Corlife, and Hannover Medical School, Hannover, Germany, studied various strategies for freeze-drying porcine heart valves. After the cellular material was removed, they freeze-dried the heart valve scaffolds with or without sucrose and hydroxyl ethylene starch, and then compared the stability and elasticity of the freeze-dried scaffolds to assess the effectiveness of these lyoprotectants in preventing degradation of the scaffold. They report their findings in the article "Freeze-dried Heart Valve Scaffolds." (http://online.liebertpub.com/doi/abs/10.1089/ten.TEC.2011.0398)

"Advances in heart valve technology are essential for improvement of patient care," says John Jansen, DDS, PhD, Methods Co-Editor-in-Chief and Professor and Chairman, Department of Biomaterials, Radboud University Nijmegen Medical Center, The Netherlands. "The authors have discerned critical methods for heart valve scaffold preservation that may fundamentally change the way that heart valve reconstruction is performed."

###

Tissue Engineering is an authoritative peer-reviewed journal published 42 times per year in print and online in three parts: Part A--the flagship journal; Part B?Reviews; and Part C?Methods. Led by Co-Editors-In-Chief Dr. Antonios Mikos, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, President and CEO, Scintellix, LLC, Raleigh, NC and Vice President, Research and Development, Avery Dennison Medical Solutions, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the Official Journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of contents and sample issues of all 3 parts are available online at http://www.liebertpub.com/ten

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Stem Cells and Development, Human Gene Therapy and HGT Methods, and Biopreservation and Biobanking. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available at http://www.liebertpub.com

Mary Ann Liebert, Inc.
140 Huguenot St., New Rochelle, NY 10801-5215
http:// http://www.liebertpub.com
Phone: 914-740-2100
800-M-LIEBERT
Fax: 914-740-2101

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

Read this article:
Freeze-dried heart valve scaffolds hold promise for heart valve replacement

Online Guided Gross Anatomy Dissector [Book and Media Reviews]

Posted on February 15, 2012 by Danzig

By Carlos A. Suárez-Quian
$59.95
Berkeley, CA, Sinauer Associates
http://www.onlinedissector.com/

Russell J. Jauta, MD Author Affiliation: Department of Surgery, Harvard Medical School, Boston, Massachusetts (rnauta@mah.harvard.edu).

From their first day of medical school, students are expected to know the anatomical relations of innervation and blood supply of organs and other body structures. During residency training and in practice, clinicians in virtually all specialties, especially surgical disciplines, perform invasive procedures or at least make diagnoses grounded in knowledge of gross anatomy.

Cadaveric prosections as seen in the Online Guided Gross Anatomy Dissector. Left, Prosected heart demonstrating the prominent coronary vasculature along with branches of the aortic arch. Right, Dissection and isolation of contents within the hepatoduodenal ligament. The hepatic artery, portal vein, and common bile duct are further identified on subsequent photographs. Images courtesy of Carlos A. Suárez-Quian, PhD.

For the student, even one armed with written anatomical guides, cadaveric dissections in gross anatomy courses have limitations. Even with the aid of dedicated prosectors, key structures are often overlooked or destroyed as a consequence of the …

View original post here:
Online Guided Gross Anatomy Dissector [Book and Media Reviews]

Dog Receives First-Ever Stem Cell Therapy in Kansas City

Posted on February 14, 2012 by ev1

KANSAS CITY, Mo. — An 11-year-old yellow Labrador suffering from severe arthritis underwent stem cell therapy on Valentine’s Day. It’s the first time a dog has received in-clinic adult stem cell therapy in Kansas City.

According to Stanley Veterinary Clinic where Jake the dog is being treated, adult animal stem cell technology uses the body`s own regenerative healing power to help cure dogs, cats and horses suffering from arthritis, hip dysplasia and tendon, ligament and cartilage injuries and other ailments.

Fat tissue is removed from the animal, the stem cells are separated from the fat and activated, and then injected into the affected areas.

Within two months of the procedure, Jake should be moving well, with little or no pain.

Severe arthritis affects up to 40 percent of the 164 million dogs and cats in the United States.

As for Jake, FOX 4’s Kim Byrnes will have an update on his condition tonight on FOX 4 News at 5 and 6.

Read the original:
Dog Receives First-Ever Stem Cell Therapy in Kansas City

Scarred Hearts Can Be Mended With Novel Stem Cell Therapy, Study Finds

Posted on February 14, 2012 by ev1

Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.

In a trial of 25 heart-attack patients, 17 who got the stem cell treatment showed a 50 percent reduction in cardiac scar tissue compared with no improvement for the eight who received standard care. The results, from the first of three sets of clinical trials generally needed for regulatory approval, were published today in the medical journal Lancet.

“The findings in this paper are encouraging,” Deepak Srivastava, director of the San Francisco-based Gladstone Institute of Cardiovascular Disease, said in an interview. “There’s a dire need for new therapies for people with heart failure, it’s still the No. 1 cause of death in men and women.”

The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University (43935MF) in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave off failure. While patients getting the stem cells showed no more improvement in heart function than those who didn’t get the experimental therapy, the theory is that new tissue regenerated by the stem cells can strengthen the heart, said Eduardo Marban, the study’s lead author.

“What our trial was designed to do is to reverse the injury once it’s happened,” said Marban, director of Cedars- Sinai Heart Institute. “The quantitative outcome that we had in this paper is to shift patients from a high-risk group to a low- risk group.”

Minimally Invasive

The stem cells were implanted within five weeks after patients suffering heart attacks. Doctors removed heart tissue, about the size of half a raisin, using a minimally invasive procedure that involved a thin needle threaded through the veins. After cultivating the stem cells from the tissue, doctors reinserted them using a second minimally invasive procedure. Patients got 12.5 million cells to 25 million cells.

A year after the procedure, six patients in the stem cell group had serious side effects, including a heart attack, chest pain, a coronary bypass, implantation of a defibrillator, and two other events unrelated to the heart. One of patient’s side effects were possibly linked to the treatment, the study found.

While the main goal of the trial was to examine the safety of the procedure, the decrease in scar tissue in those treated merits a larger study that focuses on broader clinical outcomes, researchers said in the paper.

Heart Regeneration

“If we can regenerate the whole heart, then the patient would be completely normal,” Marban said. “We haven’t fulfilled that yet, but we’ve gotten rid of half of the injury, and that’s a good start.”

While the study resulted in patients having an increase in muscle mass and a shrinkage of scar size, the amount of blood flowing out of the heart, or the ejection fraction, wasn’t different between the control group and stem-cell therapy group. The measurement is important because poor blood flow deprives the body of oxygen and nutrients it needs to function properly, Srivastava said.

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

The technology is being developed by closely held Capricor Inc., which will further test it in 200 patients for the second of three trials typically required for regulatory approval. Marban is a founder of the Los Angeles-based company and chairman of its scientific advisory board. His wife, Linda Marban, is also a founder and chief executive officer.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Please enable JavaScript to view the comments powered by Disqus.

Read the rest here:
Scarred Hearts Can Be Mended With Novel Stem Cell Therapy, Study Finds

Dogs who got stem cell therapy are well

Posted on February 14, 2012 by ev1

WALKER, Mich. (WOOD) - Dogs who received the first in-clinic stem cell therapy in West Michigan returned to the vets who treated them Monday morning.

Boris and Natasha returned to Kelley's Animal Clinic for their 60-day checkup after receiving stem cell treatment in December 2011.

Dr. James Kelley and his staff of vets removed fat tissue from the dogs and activated it with an enzyme before injecting it into their back legs.

This adult animal stem cell technology is different from the controversial embryonic stem cell therapy.

Kelley said both dogs are doing amazingly well and that the procedure has done more than just help their arthritis.

"We're finding that not only the joints are affected, the rest of the animal is affected as well," said Kelley. "The skin is better. The attitude in these dogs is much improved."

Kelley and his staff have done 16 stem cell treatments since the first on Boris and Natasha, and he said all the dogs are showing signs of improvement after a short period of time.

Scarred Hearts Can Be Mended With Stem Cell Therapy

Posted on February 14, 2012 by ev1

February 14, 2012, 3:17 PM EST

By Ryan Flinn

(Adds comment from researcher in 13th paragraph.)

Feb. 14 (Bloomberg) -- Stem cells grown from patients’ own cardiac tissue can heal damage once thought to be permanent after a heart attack, according to a study that suggests the experimental approach may one day help stave off heart failure.

The study, by researchers from Cedars-Sinai Heart Institute in Los Angeles and Johns Hopkins University in Baltimore, tested the approach in patients who recently suffered a heart attack, with the goal that repairing the damage might help stave off failure. While patients getting the stem cells showed no more improvement in heart function than those who didn’t get the experimental therapy, the theory is that new tissue regenerated by the stem cells can strengthen the heart, said Eduardo Marban, the study’s lead author.

Minimally Invasive

Heart Regeneration

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

--Editors: Angela Zimm, Andrew Pollack

#<184845.409373.2.1.99.7.25># -0- Feb/14/2012 17:13 GMT

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

More:
Scarred Hearts Can Be Mended With Stem Cell Therapy

Vet offers stem cell therapy for dogs

Posted on February 14, 2012 by ev1

COLUMBIA, SC (WIS) - Cutting-edge arthritis treatment for our four-legged family members is now available in Columbia.

Banks Animal Hospital is the first in the area to offer in-house Stem Cell therapy. It uses your pets own body to heal itself.

Take 13-year-old Maggie, for example. The energetic pup has a limp that usually keeps her from jumping or going up stairs.

"Today when everybody's out there filming her little limp it's not as pronounced because she wants to please," said Maggie's owner, Beth Phibbs. "She's just a great dog."

But a great attitude wasn't enough to repair a bad case of cervical spine arthritis.

So Monday, Beth brought Maggie to Banks Animal Hospital for the Stem Cell therapy. Like many, Beth had never heard of Stem Cell work in animals. "Until Dr. Banks mentioned it to me I was like, beg your pardon?"

"There's no down side, no side effects because you're using your own cells," said Dr Ken Banks.

Banks and his staff first gather some of Maggie's blood and fat. Both are good places to find the repair cells they're after. Adult stem cells, not the controversial embryonic kind, are then separated and spun down.

"The repair system in Maggie's body has failed," said Jason Richardson of MediVet-America. "It's fallen asleep at the wheel, we're taking these repair cells, activating them so a chronic condition like osteo arthritis to Maggie will now be an acute illness."

This kind of treatment used to take days with material being shipped across the country, but now it can be done in hours.

"The ability to do it same day, convenience, the ability to do it in clinic saves a lot of money to the doctor which he can then pass on to the patient," said Richardson.

The treatment will still run you around $2,000, but Richardson says that's half of what the similar treatment use to cost.

When it's over, Maggie should be able to live out her life pain and drug free -- something Phibbs is looking forward to.

"I'm hoping in a couple of weeks she's gonna have a new lease on life," said Phibbs.

Continued here:
Vet offers stem cell therapy for dogs

Scarred Hearts Can Be Mended With Stem Cell Therapy, Study Shows

Posted on February 14, 2012 by ev1

February 14, 2012, 3:17 PM EST

By Ryan Flinn

(Adds comment from researcher in 13th paragraph.)

Minimally Invasive

Heart Regeneration

“The patients don’t have a functional benefit in this study,” said Srivastava, who wasn’t not involved in the trial.

“We’d like to study patients who are much sicker and see if we can actually spare them early death, or the need for a heart transplant, or a device,” Eduardo Marban said.

--Editors: Angela Zimm, Andrew Pollack

#<184845.409373.2.1.99.7.25># -0- Feb/14/2012 17:13 GMT

To contact the reporter on this story: Ryan Flinn in San Francisco at rflinn@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Read the original here:
Scarred Hearts Can Be Mended With Stem Cell Therapy, Study Shows

VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

Posted on February 14, 2012 by ev1

SOUTH SAN FRANCISCO, CA--(Marketwire -02/14/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, has identified its initial Top 10 drug rescue candidates and plans to launch two formal drug rescue programs by the end of next quarter.

VistaGen's goal for each of its stem cell technology-based drug rescue programs is to generate and license a new, safer variant of a once-promising large market drug candidate previously discontinued by a pharmaceutical company no earlier than late-preclinical development.

"We are now at an advanced stage in our business model," said Shawn Singh, VistaGen's Chief Executive Officer. "After more than a decade of focused investment in pluripotent stem cell research and development, we are now at the threshold where game-changing science becomes therapeutically relevant to patients and commercially relevant to our shareholders. We have positioned our company and our stem cell technology platform to pursue multiple large market opportunities. We plan to launch two drug rescue programs by the end of the next quarter."

Over the past year, VistaGen, working with its network of strategic partners, identified over 525 once-promising new drug candidates that meet the Company's preliminary screening criteria for heart toxicity-focused drug rescue using CardioSafe 3D™, its human heart cell-based bioassay system. After internally narrowing the field to 35 compounds, VistaGen, working together with its external drug rescue advisors, including former senior pharmaceutical industry executives with drug safety and medicinal chemistry expertise, analyzed and carefully narrowed the group of 35 to the current Top 10.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants of once-promising small-molecule drug candidates. These are once-promising drug candidates discontinued by pharmaceutical companies during development due to heart toxicity, despite positive efficacy data demonstrating their potential therapeutic and commercial benefits. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans.

Additionally, VistaGen's oral small molecule prodrug candidate, AV-101 (4-Cl-KYN), is in Phase 1b development for treatment of neuropathic pain. Unlike other NMDA receptor antagonists developed previously, AV-101 readily crosses the blood-brain barrier and is then efficiently converted into 7-chlorokynurenic acid (7-Cl-KYNA), one of the most potent and specific glycineB site antagonists currently known, and has been shown to reduce seizures and excitotoxic neuronal death. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101. The Company anticipates pursuing Phase 2 development for neuropathic pain and other neurological indications, including depression, epilepsy, and/or Parkinson's disease in the event it receives additional non-dilutive development grant funding from the NIH or private foundations.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the success of VistaGen's stem cell technology-based drug rescue activities, ongoing AV-101 clinical studies, its ability to enter into drug rescue collaborations and/or licensing arrangements with respect to one or more drug rescue variants, risks and uncertainties relating to the availability of substantial additional capital to support VistaGen's research, drug rescue, development and commercialization activities, and the success of its research and development plans and strategies, including those plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at http://www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

See original here:
VistaGen Updates Pipeline of Stem Cell Technology-Based Drug Rescue Candidates

Stem Cell Treatment Might Reverse Heart Attack Damage

Posted on February 14, 2012 by ev1

MONDAY, Feb. 13 (HealthDay News) -- Stem cell therapy's promise for healing damaged tissues may have gotten a bit closer to reality. In a small, early study, heart damage was reversed in heart-attack patients treated with their own cardiac stem cells, researchers report.

The cells, called cardiosphere-derived stem cells, regrew damaged heart muscle and reversed scarring one year later, the authors say.

Up until now, heart specialists' best tool to help minimize damage following a heart attack has been to surgically clear blocked arteries.

"In our treatment, we dissolved scar and replaced it with living heart muscle. Such 'therapeutic regeneration' has long been the holy grail of cell therapy, but had never been accomplished before; we now seem to have done it," said study author Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles.

However, outside experts cautioned that the findings are preliminary and the treatment is far from ready for widespread use among heart-attack survivors.

The study, published online Feb. 14 in The Lancet, involved 25 middle-aged patients (average age 53) who had suffered a heart attack. Seventeen underwent stem cell infusions while eight received standard post-heart attack care, including medication and exercise therapy.

The stem cells were obtained using a minimally invasive procedure, according to the researchers from Cedars-Sinai and the Johns Hopkins Hospital in Baltimore.

Patients received a local anesthetic and then a catheter was threaded through a neck vein down to the heart, where a tiny portion of muscle was taken. The sample provided all the researchers needed to generate a supply of new stem cells -- 12 million to 25 million -- that were then transplanted back into the heart-attack patient during a second minimally invasive procedure.

One year after the procedure, the infusion patients' cardiac scar sizes had shrunk by about half. Scar size was reduced from 24 percent to 12 percent of the heart, the team said. In contrast, the patients receiving standard care experienced no scar shrinkage.

Initial muscle damage and healed tissue were measured using MRI scans.

After six months, four patients in the stem-cell group experienced serious adverse events compared with only one patient in the control group. At one year, two more stem-cell patients had a serious complication. However, only one such event -- a heart attack -- might have been related to the treatment, according to the study.

In a news release, Marban said that "the effects are substantial and surprisingly larger in humans than they were in animal tests."

Other experts were cautiously optimistic. Cardiac expert Dr. Bernard Gersh, a professor of medicine at Mayo Clinic, is not affiliated with the research but is familiar with the findings.

"This study demonstrates that it is safe and feasible to administer these cardiac-derived stem cells and the results are interesting and encouraging," he said.

Another specialist said that while provocative and promising, the findings remain early, phase-one research. "It's a proof-of-concept study," said interventional cardiologist Dr. Thomas Povsic, an assistant professor of medicine at the Duke Clinical Research Institute, in Durham, N.C.

And Dr. Chip Lavie, medical director of Cardiac Rehabilitation and Prevention at the John Ochsner Heart and Vascular Institute, in New Orleans, also discussed the results. He said that while the study showed that the cardiac stem cells reduced scar tissue and increased the area of live heart tissue in heart attack patients with moderately damaged overall heart tissue, it did not demonstrate a reduction in heart size or any improvement in the heart's pumping ability.

"It did not improve the ejection fraction, which is a very important measurement used to define the overall heart's pumping ability," Lavie noted. "Certainly, much larger studies of various types of heart attack patients will be needed before this even comes close to being a viable potential therapy for the large number of heart attack initial survivors."

Povsic concurred that much larger studies are needed. "The next step is showing it really helps patients in some kind of meaningful way, by either preventing death, healing them or making them feel better."

It's unclear what the cost will be, Povsic added. "What society is going to be willing to pay for this is going to be based on how much good it ends up doing. If they truly regenerate a heart and prevent a heart transplant, that would save a lot money."

Marban, who invented the stem cell treatment, said the while it would not replace bypass surgery or angioplasty, "it might be useful in treating 'irreversible' injury that may persist after those procedures."

As a rough estimate, he said that if larger, phase 2 trials were successful, the treatment might be available to the general public by about 2016.

More information

The U.S. National Heart, Lung, and Blood Institute describes current heart attack treatment.

Read the original post:
Stem Cell Treatment Might Reverse Heart Attack Damage

Stem Cells May Help Regenerate Heart Muscle

Posted on February 14, 2012 by ev1

A promising stem cell therapy approach could soon provide a way to regenerate heart muscle damaged by heart attacks.

Researchers at Cedars-Sinai Heart Institute and The Johns Hopkins University harvested stem cells from the hearts of 17 heart attack patients and after prepping the cells, infused them back into the patients' hearts. Their study is published in the current issue of The Lancet.

The patients received the stem cell infusions about three months after their heart attacks.

Researchers found that six months after treatment, patients had significantly less scarring of the heart muscle and also showed a considerable increase the amount of healthy heart muscle, compared to eight post-heart attack patients studied who did not receive the stem cell infusions. One year after, scar size was reduced by about 50 percent.

"The damaged tissue of the heart was replaced by what looks like healthy myocardium," said Dr. Peter Johnston, a study co-author and an assistant professor of medicine at The Johns Hopkins University School of Medicine. "It's functioning better than the damaged myocardium in the control subjects, and there's evidence it's starting to contract and generate electrical signals the way healthy heart tissue does."

While this research is an early study designed to demonstrate that this stem cell therapy is safe, cardiologists say it's an approach that could potentially benefit millions of people who have suffered heart attacks. Damage to the heart muscle is permanent and irreparable, and little can be done to compensate for loss of heart function.

"In the U.S., six million patients have heart failure, and the vast majority have it because of a prior heart attack," said Johnston.

The damaged scar tissue that results from a heart attack diminishes heart function, which can ultimately lead to enlargement of the heart.

At best, Johnston said, there are measures doctors can try to reduce or compensate for the damage, but in many cases, heart failure ultimately sets in, often requiring mechanical support or a transplant.

"This type of therapy can save people's lives and reduce the chances of developing heart failure," he said.

Cardiac Regeneration A Promising Field

Other researchers have also had positive early results in experiments with stem cell therapy using different types of cells, including bone marrow cells and a combination of bone marrow and heart cells.

"It's exciting that studies using a number of different cell types are yielding similar results," said Dr. Joshua Hare, professor of cardiology and director of the University of Miami Interdisciplinary Stem Cell Institute.

The next steps, he said, include determining what the optimal cell types are and how much of the cells are needed to regenerate damaged tissue.

"We also need to move to larger clinical trials and measure whether patients are improving clinically and exhibiting a better quality of life after the therapy."

In an accompanying comment, Drs. Chung-Wah Siu amd Hung-Fat Tse of the University of Hong Kong wrote that given the promising results of these studies, health care providers will hopefully recognize the benefits that cardiac regeneration can offer.

And Hare added that someday, this type of regeneration can possibly offer hope to others who suffered other types of organ damage.

"This stategy might work in other organs," he said. "Maybe this can work in the brain, perhaps for people who had strokes."

Read the rest here:
Stem Cells May Help Regenerate Heart Muscle

Mitomics Announces U.S. Sales and Marketing Agreement with LabMD

Posted on February 14, 2012 by ev1

THUNDER BAY, Ontario--(BUSINESS WIRE)--

Mitomics, a world leader in the research and development of mitochondrial genome-based products, today announced a non-exclusive agreement with LabMD, Inc., an Atlanta-based clinical pathology laboratory, to market Mitomics’ flagship product, the Prostate Core Mitomic Test™ (PCMT), in the United States.

“We are pleased to partner with LabMD to make PCMT available to their urology customers nationwide,” said Robert Poulter, president and chief executive officer of Mitomics. “LabMD has an outstanding reputation and strong track record of providing exceptional service to its customers. They continue to integrate cutting-edge technologies into their lab, and we have found great synergies between our two companies. This agreement supports our ongoing strategy to expand access to our prostate cancer testing technology through strategic collaborations as well as through direct sales by our field force.”

PCMT is a highly advanced test, based on the science of mitochondrial DNA (mtDNA), that accurately identifies a biomarker that can indicate the presence of cancerous cells using previously obtained prostate biopsy tissue. PCMT takes advantage of a tumor’s cancerization field effect to identify molecular changes and enable detection of missed tumors. The test’s sensitivity of 84 percent and ability to accurately rule out prostate cancer with a negative predictive value of 91 percent can provide reliable information to physicians and patients confronted with a possible prostate cancer diagnosis.

“Mitomics’ PCMT fits well within our current portfolio of clinical pathology tests, and we look forward to offering urologists this highly accurate test for patients with suspected prostate cancer who have a negative initial biopsy outcome,” said Michael Daugherty, founder, chief executive officer and president of LabMD. “We are committed to enhancing our service offerings and are excited to be working closely with Mitomics to increase the availability of PCMT.”

Prostate cancer is the most commonly diagnosed cancer in males and the second leading cause of cancer death in the U.S. Every year, more than 230,000 American men are diagnosed with prostate cancer, and more than 30,000 die from the disease. If detected early, prostate cancer is often treatable. It is estimated that well over 1 million prostate biopsies are performed annually in the U.S., and although approximately 70 percent of all initial prostate biopsies are negative, it has been found that anywhere from 25 to 60 percent of these are positive on second or subsequent biopsy.

About the Prostate Core Mitomic Test™ (PCMT)

A prostate cancer biopsy is neither an easy nor painless procedure and can result in multiple complications. It only samples a small fraction of the prostate gland, potentially missing the tumor and contributing to a high false negative rate – even in second biopsies. With the highly sensitive PCMT, you can know more by getting far more accurate and reliable results from biopsy tissue. PCMT is a highly advanced, proprietary test based on the science of mitochondrial DNA (mtDNA). Using previously obtained prostate biopsy tissue, PCMT can determine the presence of malignant cells via a cancerization field effect by detecting underlying molecular alterations in normal-appearing tissue. This is all performed quickly and easily with a simple lab test. For more information or to order PCMT, please visit the PCMT web page.

About Mitomics

Mitomics is the world leader in the research and development of mitochondrial DNA (mtDNA)-based biomarkers – a new and innovative approach to the detection of cancer and other disease states. Leveraging its unparalleled insights into the role of mitochondria in cancer, the company is developing an extensive and proprietary portfolio of molecular tests that address significant unmet needs in oncology and gynecology, including those for the early detection of prostate and breast cancer, as well as a test for endometriosis. Mitomics currently markets the Prostate Core Mitomic Test™, a highly accurate laboratory developed test for detecting the absence or presence of cancerous cells using existing prostate biopsy tissue, and plans to launch several additional breakthrough molecular tests based on its Mitomic Technology™ in the coming years. The company is headquartered in Thunder Bay, Ontario, Canada. For more information, please visit http://www.mitomicsinc.com.

About LabMD, Inc.

LabMD is a privately held anatomic and clinical pathology laboratory that focuses on the Urology office based market. Through expert pathology practiced by our highly experienced uropathologists and LabMD's unique software solutions that streamline and bring efficiency to our clients, LabMD builds strong long-term client relationships. For more information, please contact LabMD at 678.443.2331.

Continue reading here:
Mitomics Announces U.S. Sales and Marketing Agreement with LabMD

Pronova BioPharma ASA: Expanding the Pharmaceutical Business into Clinical Nutrition

Posted on February 14, 2012 by ev1

14 February 2012, Lysaker, Norway: Pronova BioPharma today announced results for the fourth quarter and full year 2011. Fourth quarter revenues were NOK 444.3 million, up 14 percent from a year before, and revenues for the year ended 31 December 2011 were NOK 1 668.9 million, up 2 percent from last year. EBITDA was NOK 197.1 million in the fourth quarter, up 53 percent year-on-year, and was NOK 705.3 million for the full year, up 13 percent from last year.

End-user demand in Pronova BioPharma`s current eight largest markets, as measured by IMS, grew by 5 percent in 2011, representing total volumes of 1 273 tonnes. This represents USD 1.4 billion in drug sales, with Omacor®/Lovaza(TM) maintaining its status as a blockbuster product. During the year, GSK reached its expected inventory target for 2011. The reduction in demand was partially offset by higher off-take from other partners in Europe and Asia. Omacor®/Lovaza(TM) is currently sold in 57 markets, and the Group continues to expand its geographic reach.

The Board of Directors propose to adjust the existing dividend policy to between 40 and 60 percent of net profit adjusted for pre-tax amortisation costs. The decision reflects the continued strong cash generation of Pronova BioPharma and the Company`s commitment to provide competitive returns to investors. The Company believes that adjusting for non cash amortisation costs better emphasises the strong cash conversion in the dividend policy. Furthermore, a more narrow range of 40 to 60 percent of adjusted net profit allows Pronova BioPharma to give a more targeted guidance to the financial community going forward. The Company will continue to evaluate annual dividends against the objectives of maintaining a solid financial position and investments to grow the business.

In line with the revised dividend policy, the Board of Directors propose a first dividend of NOK 0.5 per share for 2011, corresponding to approximately 50 percent of net profit adjusted for pre-tax amortisation cost. This reflects the significant progress made towards the Company`s strategic objectives in 2011, which has strengthened the Company`s financial position and diversified its future cash generation capabilities.

Based on current market conditions, Pronova BioPharma maintains its outlook for 2012, with shipments in line with underlying end-user demand and launches in new markets. Supply prices, as measured by the revenue-to-shipment ratio are expected to be in line with 2011 levels. The Company expects, all other things being equal, revenue and EBITDA growth in 2012.

However, as previously communicated, there is a risk of loss of exclusivity in Europe, where patents in most countries expired 30 months ago. There is also a risk of generic launch in the USA if the US District Court for the District of Delaware (District Court) rules against Pronova BioPharma in the litigation against Teva and Par, the US Food and Drug Administration (FDA) grants approval to the generic companies and API supply is available in sufficient volume. The Company expects a ruling within the next three months.

The Group today announced plans to expand its pharmaceutical business into clinical nutrition. Clinical nutrition is nutrition taken under medical supervision and is provided in either enteral or parenteral form. The omega-3 market for clinical nutrition is estimated at 500 tonnes in 2011 and is expected to double in size within five years.

Pronova BioPharma plans to develop new clinical nutrition products in collaboration with leading scientists and commercial partners. Products will be differentiated from existing offerings through such factors as concentration and purity levels, quality assurance, and health claims/scientific documentation.

Pronova BioPharma also continues to make progress in its research efforts to develop new drugs in the metabolic/cardiovascular/inflammatory treatment areas. The Group`s lead pipeline candidate PRC-4016, a new chemical entity for the treatment of combined dyslipidemia (abnormal blood lipid levels), is currently in Phase I trials. Dyslipidemia has been shown to play an important role in the development of cardiovascular risk. PRC-4016 is a structurally modified omega-3 fatty acid, which has shown in pre-clinical studies to have potent triglyceride and bad (non-HDL) cholesterol lowering effects while raising good (HDL) cholesterol. The trial is a double-blind, placebo-controlled, single and multiple oral dose study to investigate the safety, tolerability and pharmacokinetics of PRC-4016. The study, conducted in healthy volunteers, is being performed in the UK. The trial is progressing well and top line results are expected to be announced in Q2 2012.

In November 2011, Pronova BioPharma announced that it will develop a consumer healthcare business, entering the fast-growing Omega-3 consumer healthcare market. The business will initially target the high concentrate dietary supplement market, which is expected to double in size in the next five years. Since the announcement, Pronova BioPharma has made substantial progress in developing this business. The manufacturing facility in Sandefjord, Norway has been selected to serve the consumer healthcare business and the necessary modifications are being implemented. The Company has also strengthened the management team with the appointment of Claus Kjærsgaard as VP of Consumer Healthcare and a number of experienced professionals are in the process of being hired for the new division. Claus brings 15 years of consumer healthcare experience across a diversity of categories, distribution channels and geographical environments.

Pronova BioPharma continues to extend its manufacturing advantages. In June 2011, the Group announced a target of increasing yield by 50 percent by the end of 2014 compared to 2009 levels. Pronova BioPharma is well on its way to achieving that target.

Pronova BioPharma`s Chief Executive Officer Morten Jurs commented, "In 2011, we continued to generate strong cash flow and made significant progress towards our strategic objectives. Our core pharmaceutical business continued to grow, and we launched our product in new markets. On the manufacturing side, we improved yield to further strengthen our competitive advantage in manufacturing versus potential market entrants. With our progress in R&D, expansion into clinical nutrition and our plans to launch a consumer healthcare business, we have made Pronova BioPharma a more diversified company and created new sources of growth. "

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)Report Q4 11
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Pronova BioPharma ASA via Thomson Reuters ONE
HUG#1585270

Research and Markets: South Africa In Vitro Diagnostics Market Outlook to 2017

Posted on February 14, 2012 by ev1

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/d22d0e/south_africa_in_vi) has announced the addition of GlobalData 's new report "South Africa In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" to their offering.

GlobalData's new report, South Africa In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture provides key market data on the South Africa In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope:

Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017. 2010 company shares and distribution shares data for each of the seven market categories. Global corporate-level profiles of key companies operating within the market.

Reasons to Buy:

Develop business strategies by identifying the key market categories and segments poised for strong growth. Develop market-entry and market expansion strategies. Design competition strategies by identifying who-stands-where in the South Africa In Vitro Diagnostics competitive landscape. Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. What are the key distribution channels and what's the most preferred mode of product distribution? Identify, understand and capitalize.

Companies Mentioned:

Abbott Laboratories Alere Inc. Ani Labsystems Ltd Oy Beckman Coulter, Inc. Becton, Dickinson and Company bioMerieux S.A. Bio-Rad Laboratories, Inc. Chembio Diagnostic, Inc. DIAGNOSTICA STAGO, Inc. DiaSorin S.p.A F. Hoffmann-La Roche Ltd. Gen-Probe Incorporated Grifols, S.A. HORIBA, Ltd. Hologic, Inc. Immucor, Inc. Life Technologies Corporation Mindray Medical International Limited Ortho-Clinical Diagnostics Inc. PerkinElmer, Inc. Phadia AB Qiagen N.V. Siemens Healthcare Sysmex Corporation Thermo Fisher Scientific Inc.

For more information visit http://www.researchandmarkets.com/research/d22d0e/south_africa_in_vi

Original post:
Research and Markets: South Africa In Vitro Diagnostics Market Outlook to 2017

Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

Posted on February 14, 2012 by ev1

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

http://www.reportlinker.com/p0771112/Leading-Microbiology-Market-Players-Insightful-Profiles-of-Major-Suppliers-and-Emerging-Market-Entrants.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic

This report presents strategic assessments of leading market players and emerging suppliers with innovative technologies and products in terms of their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies.

Contains 90 pages

Table of Contents- Abbott

- Affymetrix

- Beckman Coulter/Danaher

- Becton Dickinson

- bioMerieux

- Bio-Rad

- Cepheid

- Diamedix

- DiaSorin

- Eiken Chemical

- Enzo Biochem

- Fujirebio

- Gen-Probe

- Hologic

- ID Biomedical

- Innogenetics/Solvay

- Ortho-Clinical Diagnostics

- Kreatech

- Life Technology

- Lonza

- Nanogen/Elitech

- Novartis Diagnostics

- Qiagen

- Roche

- Scienion

- Sequenom

- SeraCare

- Siemens

- Takara Bio

- Thermo Fisher

- Wallac

- Wako

To order this report:In Vitro Diagnostic Industry: Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

Visit link:
Leading Microbiology Market Players: Insightful Profiles of Major Suppliers and Emerging Market Entrants

Select Page ::